By: ChinaBio® Today
March 25, 2013 at 10:58 AM EDT
Cellular Biomedicine Starts China Trial of Liver Cancer Treatment
Cellular Biomedicine Group has started a clinical trial in China of an innovative personalized treatment for liver cancer. Through a collaboration with Shanghai's PLA 85 Hospital, the company will test its TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy in patients with hepatocellular carcinoma (HCC). CBMG has facilities in Shanghai and WuXi, though its headquarters are in Palo Alto, California. More details.... Stock Symbol: (OTCQB: CBMG) Share this with colleagues: // //
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here